Actively Recruiting
The Impact of Phase I Cardiac Rehabilitation on the Prognosis of AMI Patients After PCI
Led by Han Yaling, MD · Updated on 2024-05-09
1100
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Previous research has confirmed that patients undergoing percutaneous coronary intervention (PCI) can benefit from cardiac rehabilitation programs. However, there is a paucity of studies on Phase I cardiac rehabilitation commenced within three days following PCI in patients with acute myocardial infarction (AMI). Consequently, the objective of the study is to demonstrate whether Phase I cardiac rehabilitation can improve the prognosis at 12 months when compared with the control group. The primary endpoint is the Seattle Angina Questionnaire (SAQ) score at 12 months for the patients. The principal hypothesis of the study is that Phase I cardiac rehabilitation will improve the long-term prognosis for AMI patients at 12 months after PCI.
CONDITIONS
Official Title
The Impact of Phase I Cardiac Rehabilitation on the Prognosis of AMI Patients After PCI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute myocardial infarction (including STEMI and NSTEMI) treated in the coronary care unit for more than 12 hours after emergency PCI
- Expected to meet discharge criteria without needing repeat PCI during current hospital stay
- No chest pain episodes within 8 hours and no recurrence of myocardial infarction; hemodynamically stable
- No further increase in cardiac biomarkers such as CK-MB and cardiac troponins
You will not qualify if you...
- Killip class III or higher, or symptoms/signs of acute pulmonary edema and respiratory distress
- Malignant arrhythmias causing hemodynamic instability or life-threatening conditions
- Mechanical heart lesions such as ventricular wall rupture or valve/tendon rupture
- Not yet weaned off ECMO, IABP, temporary pacemakers, or CRRT
- Liver or kidney dysfunction (transaminase >3 times upper limit or EGFR <30 ml/min/1.73m²) or advanced malignant tumors
- Unable to perform exercise rehabilitation due to orthopedic or psychiatric diseases
- Language impairment
- Currently in systematic training or other clinical trials without primary endpoint collected
- Considered unsuitable for participation by researchers or lack of informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
General Hospital of Northern Theater Command
Shenyang, Liaoning, China, 110016
Actively Recruiting
Research Team
Y
Ya-Ling Han, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here